MTMeryem Khadija Talbo

Meryem Khadija Talbo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Meryem Khadija Talbo has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Automated insulin delivery and lower burden of hypoglycemia in type 1 diabetes: a prospective analysis of the BETTER registry

    by Meryem K. Talbo, Tricia M. Peters, Jean François Yale, Courtney A. South, Remi Rabasa-Lhoret, Anne-Sophie Brazeau

  • Open Access

    Prandial Insulin Adjustments in the Context of Gastroparesis and Type 1 Diabetes: A Mixed-Methods Study

    by Meryem K. Talbo, Alexandra Katz, Amelie Roy-Fleming, Sarah Haag, Tricia M. Peters, Rémi Rabasa-Lhoret, Jean-François Yale, Barbara Kelly, Jade Maria Moisan, Anne-Sophie Brazeau

  • Open Access

    Screening for Fear of Hypoglycemia in Type 1 Diabetes: Aligning Clinical Practice With Current Guidelines

    by Meryem K. Talbo, Tricia M. Peters, Jean-François Yale, Alexandra Katz, Claude Laforest, Andréanne Vanasse, Jessica C. Kichler, Remi Rabasa-Lhoret, Anne-Sophie Brazeau

  • Open Access

    Despite lower haemoglobin A1c with second‐generation automated insulin delivery systems, mental burden remains high for all adults with type 1 diabetes: A BETTER registry analysis

    by Zekai Wu, Laure Alexandre‐Heymann, Maha Lebbar, Meryem K. Talbo, Aude Bandini, Tamanna Chahal, Caroline Grou, Virginie Messier, Valérie Boudreau, Anne‐Sophie Brazeau, et al.

    Objective: We aim to compare second‐generation automated insulin delivery systems (AIDs) with other treatment modalities regarding both glucose management outcomes and person‐reported outcomes/experiences (PROs/PREs, measured by the Hypoglycemia Fear Survey, Hypoglycemic Confidence Scale, Hyperglycemia Avoidance Scale, Diabetes Distress Scale, Pittsburgh Sleep Quality Index, Well‐being Scale, and treatment satisfaction) among adults with type 1 diabetes. Research design and methods: Cross‐sectional analysis of the Canadian BETTER type 1 diabetes registry. Adult participants were divided into five groups: second‐generation AIDs, first‐generation AIDs, continuous glucose monitoring (CGM) + pump, CGM + multiple daily injections (MDI), and non‐CGM using MDI or pump. Generalized linear models were used to assess differences between the second‐generation AID group and each of the other groups, with p < 0.05 considered significant. Results: Among 1731 participants (69.2% females), mean age was 45.3 ± 15.3 years with 24.7 ± 16.0 years of diabetes. The second‐generation AID group had the highest proportion of achieving target haemoglobin A1c ≤ 7% (58.1%) compared to 40.6% in the first‐generation AID group, 40.5% in the Pump + CGM group, 37.3% in the MDI + CGM group, and 32.3% in the non‐CGM group, even after adjustment for multiple imbalanced characteristics ( p < 0.001). While second‐generation AID users reported higher treatment satisfaction, no other differences in measures of PROs/PREs were found between second‐generation AID and other groups. Elevated diabetes distress (55%) and poor sleep quality (63%) remained common across all treatment groups, and even among those who had reached the optimal HbA1c target (48% and 60%, respectively). Conclusions: In real‐world settings, second‐generation AIDs were associated with lower haemoglobin A1c and higher treatment satisfaction but not better PROs/PREs. Mental burden remained high despite the use of advanced diabetes technologies and optimal glucose management.


  • Open Access

    Exercise and Glycemic Management in Females and Women With Diabetes: The Role of Sex and Gender Across the Lifespan

    by Tricia M. Peters, Anne-Sophie Brazeau, Lia Bally, Alexa Govette, Elsa Heyman, Mary E. Jung, Céline I. Laesser, Élodie Lespagnol, Jessica E. Logan, Zeinab Momeni, et al.


  • Open Access

    Strategies to Reduce Hyperglycemia-Related Anxiety in Elite Athletes with Type 1 Diabetes: A Qualitative Analysis

    by Alexandra Katz, Aidan Shulkin, Marc-André Fortier, Jane E. Yardley, Jessica Kichler, Asmaa Housni, Meryem K. Talbo, Rémi Rabasa-Lhoret, Anne-Sophie Brazeau

    Objective: Managing blood glucose levels is challenging for elite athletes with type 1 diabetes (T1D) as competition can cause unpredictable fluctuations. Hyperglycemia-related anxiety (HRA) likely affects performance and diabetes management, but research is limited. This study investigates current strategies employed to mitigate HRA during competition and the development of alternative approaches. Research Design and Methods: Elite athletes with TID, aged > 14 who self-reported HRA during competition were recruited. Elite athletes were defined as individuals exercising >10 hours per week whose athletic performance has achieved the highest competition level. 60 to 90-minute virtual semi-structured interviews were analyzed using an Interpretative Phenomenological Analysis. Results: Ten elite athletes with T1D (average age 25 ± 3 years; T1D duration 12 ± 8 years; # of competitions per year 27 ± 19; training time per week 12 ± 6 hours) reported the strategies they currently use to mitigate HRA. These strategies include managing insulin and nutrition intake, embracing social support networks, using technology, practicing relaxation techniques, establishing routines, performing pre-competition aerobic exercise, and maintaining adequate sleep hygiene. Several additional approaches that could be implemented were identified including establishing targeted support networks, developing peer-reviewed resources on HRA, ensuring support teams have sufficient tools, and improving existing technology. Conclusions: Elite athletes with T1D use physiological and psychological strategies to mitigate HRA during competition. This finding highlights the need for increased support and education for these athletes, and advancements in technology. Targeted strategies and personalized approaches are also needed to optimize performance and diabetes management in this population.

  • Open Access

    Overweight and Obesity in People Living With Type 1 Diabetes: A Cross‐Sectional Analysis of the BETTER Registry

    by Marie‐Laure Lalanne‐Mistrih, Anne Bonhoure, Virginie Messier, Valérie Boudreau, Maha Lebbar, Meryem K. Talbo, Cathy J. Sun, Aude Bandini, Laurence Secours, Virginie Calderon, et al.

    Aims: The prevalence and associations of overweight and obesity in Canadian adult people living with type 1 diabetes (PWT1D) are poorly documented. In a cohort of PWT1D patients, this study assesses (i) overweight and obesity frequencies and associated PWT1D clinicodemographic characteristics, (ii) diabetes characteristics, and (iii) the use of noninsulin adjunctive agents.Materials and Methods: Cross‐sectional analysis of self‐reported data from the BETTER registry: 1091 adult PWT1D (aged 44.4 ± 15.0 years; 32% HbA1cp < 0.001). Compared to other PWT1D, those living with obesity reported higher HbA1c (p < 0.05), less frequent hypoglycemia (p < 0.05), more cardiovascular diseases (p < 0.003), retinopathy, neuropathy, depression treatment as well as noninsulin adjunctive agent use (all p < 0.001). Logistic regression showed that living with overweight/obesity was associated with male sex, being treated for cardiorenal therapies, depression, diabetes duration, and total daily insulin doses.Conclusions: Overweight or obesity affects over half of adult PWT1D in the Canadian BETTER registry and is associated with higher HbA1c levels, higher total daily insulin doses, more chronic diabetes complications and noninsulin adjunctive agent use, a worse cardiometabolic profile, and lower hypoglycemia frequency.


  • Open Access

    TheSupport-ProOnline Training Platform: Increasing Health Care Professionals’ Confidence and Knowledge in Treating People Living With Type 1 Diabetes

    by Alexandra Katz, Amélie Roy-Fleming, Asmaa Housni, Meryem K. Talbo, Sarah Haag, Rémi Rabasa-Lhoret, Anne-Sophie Brazeau

    Alexandra Katz, Amélie Roy-Fleming, Asmaa Housni, Meryem K. Talbo, Sarah Haag, Rémi Rabasa-Lhoret, Anne-Sophie Brazeau; The Support-Pro Online Training Pla Alexandra Katz, Amélie Roy-Fleming, Asmaa Housni, Meryem K. Talbo, Sarah Haag, Rémi Rabasa-Lhoret, Anne-Sophie Brazeau; The Support-Pro Online Training Pla


  • Exploring Technology’s Influence on Health Behaviours and Well-being in Type 1 Diabetes: a Review

    by Reid D. McClure, Meryem K. Talbo, Anne Bonhoure, Joséphine Molveau, Courtney A. South, Maha Lebbar, Zekai Wu

    Purpose of Review Maintaining positive health behaviours promotes better health outcomes for people with type 1 diabetes (T1D). However, implementing these behaviours may also lead to additional management burdens and challenges. Diabetes technologies, including continuous glucose monitoring systems, automated insulin delivery systems, and digital platforms, are being rapidly developed and widely used to reduce these burdens. Our aim was to review recent evidence to explore the influence of these technologies on health behaviours and well-being among adults with T1D and discuss future directions. Recent Findings Current evidence, albeit limited, suggests that technologies applied in diabetes self-management education and support (DSME/S), nutrition, physical activity (PA), and psychosocial care areas improved glucose outcomes. They may also increase flexibility in insulin adjustment and eating behaviours, reduce carb counting burden, increase confidence in PA, and reduce mental burden. Summary Technologies have the potential to promote health behaviours changes and well-being for people with T1D. More confirmative studies on their effectiveness and safety are needed to ensure optimal integration in standard care practices.


  • Does Insulin Delivery Technology Change Our Relationship with Foods? A Scoping Review

    by Courtney A. South, Meryem K. Talbo, Amélie Roy-Fleming, Tricia M. Peters, Daiva E. Nielsen, Sylvain Iceta, Anne-Sophie Brazeau

    Introduction: Automated insulin delivery (AID) systems reduce burden and improve glycemic management for people with type 1 diabetes (PwT1D) by automatically adjusting insulin as a response to measured glucose levels. There is a lack of evidence on AID and nutrition variables such as dietary intake, eating behaviors, and disordered eating. Objectives: This scoping review aims to provide a summary of the literature regarding AID and nutrition variables and to identify gaps that require further investigation. Methods: Two researchers conducted a blinded search of Medline (OVID) and PubMed for studies, including AID use (compared to non-AID use) and nutrition variables. Studies from January 2000 to July 2023 were included, as were PwT1D of all ages. Results: A total of 3132 articles were screened for appropriateness. After exclusions, 7 studies were included (2017–2023): 4 qualitative, 1 crossover, 1 randomized controlled, and 1 observational. Studies included adolescents ( n = 1), adults ( n = 3) or both ( n = 2), and all ages ( n = 1). In quantitative studies, AID was associated with lower eating distress (−0.43 ± 0.12, P = 0.004) and higher quality of life (3.1, 95% confidence interval [CI]: 0.8–5.4, P = 0.01), but not grams of carbohydrates at meals (1.0; 95% CI: −0.7 to 3.0; P = 0.24) and snacks (0.004; 95% CI: −0.8 to 0.8; P = 0.99) compared to non-AID use. In qualitative studies, AID increased the frequency and portions of food intake and led to less dietary control from parents. AID users reported eating foods higher in energy density. PwT1D were less worried about achieving accurate carbohydrate counting (CC) when using AID. Conclusions: AID use appears to influence eating behaviors, dietary patterns, and CC, although evidence was limited. AID may reduce food management burden due to the perception that AID can correct for CC inaccuracy. Significance: Further research needs to determine if AID allows for simplification of CC and improves eating behaviors while maintaining glycemic stability.